Edition:
United Kingdom

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

62.51USD
23 Aug 2019
Change (% chg)

$-1.71 (-2.66%)
Prev Close
$64.22
Open
$64.07
Day's High
$64.67
Day's Low
$62.19
Volume
3,119,183
Avg. Vol
2,358,340
52-wk High
$79.61
52-wk Low
$60.32

Latest Key Developments (Source: Significant Developments)

Gilead Announces Latest Data In Ongoing HIV Cure Research Program
Tuesday, 23 Jul 2019 

July 23 (Reuters) - Gilead Sciences Inc ::GILEAD ANNOUNCES LATEST DATA IN ONGOING HIV CURE RESEARCH PROGRAM.GILEAD SCIENCES INC - NEW STUDIES EVALUATE AGENTS WITH POTENTIAL ROLE IN ELIMINATING HIV VIRAL RESERVOIR.GILEAD SCIENCES - PHASE 1 AND PRECLINICAL STUDY RESULTS DEMONSTRATE THAT TLR7 AGONISTS VESATOLIMOD (GS-9620) AND GS-986 CAN INDUCE IMMUNE ACTIVATION.GILEAD SCIENCES INC - GS-986 WAS WELL-TOLERATED WITH NORMAL COMPLETE BLOOD COUNT AND MAINTENANCE OF VIRAL SUPPRESSION.GILEAD SCIENCES INC - VESATOLIMOD WAS WELL-TOLERATED AT ALL DOSES, WITH NO DRUG-RELATED GRADE 3 OR 4 ADVERSE EVENTS, NO RELATED SERIOUS ADVERSE EVENTS.  Full Article

Gilead Sciences Under Transition Agreement With Mchutchison, Co To Pay $1.1 Mln To Mchutchison
Wednesday, 17 Jul 2019 

July 17 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES SAYS UNDER TRANSITION AGREEMENT WITH MCHUTCHISON, CO TO PAY MCHUTCHISON LUMP SUM PAYMENT OF $1.1 MILLION - SEC FILING.  Full Article

Gilead Announces Intent To Submit New Drug Application For Filgotinib To U.S. FDA This Year
Tuesday, 2 Jul 2019 

July 1 (Reuters) - Gilead Sciences Inc ::GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR.  Full Article

Gilead And Carna Biosciences Announce Research And Development Collaboration
Tuesday, 25 Jun 2019 

June 24 (Reuters) - Gilead Sciences Inc ::GILEAD AND CARNA BIOSCIENCES ANNOUNCE RESEARCH AND DEVELOPMENT COLLABORATION TO DEVELOP NOVEL IMMUNO-ONCOLOGY THERAPIES.GILEAD SCIENCES- CARNA WILL RECEIVE AN UPFRONT PAYMENT OF $20 MILLION & IS ELIGIBLE TO RECEIVE UP TO ADDITIONAL $450 MILLION IN POTENTIAL MILESTONE PAYMENTS.CARNA WILL ALSO RECEIVE ROYALTIES ON FUTURE NET SALES.CARNA WILL ALSO RECEIVE ROYALTIES ON FUTURE NET SALES.GILEAD WILL ALSO HAVE EXCLUSIVE ACCESS TO CARNA'S PROPRIETARY LIPID KINASE DRUG DISCOVERY PLATFORM.GILEAD- UNDER TERMS, CO WILL LICENSE FROM CARNA WORLDWIDE RIGHTS TO DEVELOP & COMMERCIALIZE INHIBITORS AGAINST AN UNDISCLOSED IMMUNO-ONCOLOGY TARGET.  Full Article

Biocartis And Kite Sign Agreement For Development Of Assays Supporting Kite's Therapies
Saturday, 1 Jun 2019 

June 1 (Reuters) - Biocartis Group NV ::BIOCARTIS GROUP NV SAYS BIOCARTIS AND KITE SIGN AGREEMENT FOR DEVELOPMENT OF ASSAYS SUPPORTING KITE'S THERAPIES.BIOCARTIS GROUP NV SAYS FINANCIAL DETAILS ON AGREEMENT WITH KITE ARE NOT DISCLOSED..  Full Article

Temasek Holdings (Private) Ltd Dissolves Share Stake In Tencent Music, Gilead Sciences; Cuts in Alibaba
Wednesday, 15 May 2019 

May 15 (Reuters) - Temasek Holdings (Private) Ltd::TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN TENCENT MUSIC ENTERTAINMENT GROUP - SEC FILING.TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN GILEAD SCIENCES INC.TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN ALIBABA GROUP HOLDING LTD BY 4.7 PERCENT TO 26.1 MILLION SPONSORED ADSS.TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN FARFETCH LTD BY 27.2 PERCENT TO 3.3 MILLION CLASS A ORDINARY SHARES.TEMASEK HOLDINGS (PRIVATE) LTD TAKES SHARE STAKE OF 167,620 SHARES IN SVMK INC.TEMASEK HOLDINGS (PRIVATE) LTD TAKES SHARE STAKE OF 442,021 SHARES IN AMYRIS INC.TEMASEK HOLDINGS (PRIVATE) LTD - CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2019 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DECEMBER 31, 2018.  Full Article

Gilead Sciences And Goldfinch Bio Announce Strategic Collaboration To Develop New Therapies For Kidney Disease
Wednesday, 8 May 2019 

May 8 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES AND GOLDFINCH BIO ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NOVEL THERAPIES FOR KIDNEY DISEASE.GILEAD SCIENCES INC - UNDER TERMS OF AGREEMENT, GOLDFINCH WILL RECEIVE $55 MILLION IN UPFRONT PAYMENTS.GILEAD SCIENCES INC - GOLDFINCH IS ALSO ELIGIBLE TO RECEIVE UP TO $1.95 BILLION IN POTENTIAL PAYMENTS.GILEAD SCIENCES INC - COLLABORATION DOES NOT INCLUDE GOLDFINCH'S EXISTING PROGRAMS, GFB-887 AND GFB-024, FOR WHICH GOLDFINCH WILL RETAIN ALL RIGHTS.GILEAD SCIENCES - UNDER MULTI-YEAR COLLABORATION, CO HAS EXCLUSIVE OPTIONS TO LICENSE WORLDWIDE RIGHTS TO CERTAIN PRODUCTS.  Full Article

Gilead, Insitro To Develop Novel Therapies For Nonalcoholic Steatohepatitis
Tuesday, 16 Apr 2019 

April 16 (Reuters) - Gilead Sciences Inc ::GILEAD AND INSITRO ANNOUNCE STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL THERAPIES FOR NONALCOHOLIC STEATOHEPATITIS.GILEAD SCIENCES - UNDER TERMS OF THE 3-YEAR COLLABORATION WITH INSITRO, INSITRO’S PROPRIETARY PLATFORM WILL BE USED TO CREATE DISEASE MODELS FOR NASH.GILEAD SCIENCES - UNDER INSITRO AGREEMENT, INSITRO TO GET ADDITIONAL NEAR-TERM PAYMENTS UP TO $35 MILLION BASED ON OPERATIONAL MILESTONES.GILEAD SCIENCES - UNDER INSITRO AGREEMENT, INSITRO ELIGIBLE TO RECEIVE UP TO $200 MILLION FOR ACHIEVEMENT OF CERTAIN MILESTONES FOR 5 GILEAD TARGETS.GILEAD SCIENCES - UNDER INSITRO AGREEMENT, INSITRO WILL RECEIVE AN UPFRONT PAYMENT OF $15 MILLION.  Full Article

Gilead Submits Supplemental NDA To USFDA For Once-Daily Descovy For Hiv Pre-Exposure Prophylaxis
Friday, 5 Apr 2019 

April 5 (Reuters) - Gilead Sciences Inc ::GILEAD SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR ONCE-DAILY DESCOVY® FOR HIV PRE-EXPOSURE PROPHYLAXIS.GILEAD SCIENCES INC - PRIORITY REVIEW VOUCHER WAS SUBMITTED WITH FILING, LEADING TO AN ANTICIPATED REVIEW TIME OF SIX MONTHS.  Full Article

Gilead Sciences Says CEO's FY 2018 Total Compensation Was $25.96 Million - SEC Filing
Monday, 25 Mar 2019 

March 25 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES INC SAYS CEO JOHN MILLIGAN'S FY 2018 TOTAL COMPENSATION WAS $25.96 MILLION VERSUS $15.44 MILLION IN FY 2017 - SEC FILING.GILEAD SCIENCES INC SAYS SAYS RATIO OF CEO ANNUAL TOTAL COMPENSATION TO MEDIAN EMPLOYEE’S TOTAL ANNUAL COMPENSATION FOR FISCAL YEAR 2018 IS 158 TO 1.  Full Article

UPDATE 2-GSK's long acting HIV injection gets boost from study

* GSK up against competition from Gilead's 3-drug combo (Releads, adds background on rivalry with Gilead)